SBIO logo

ALPS Medical Breakthroughs ETF (SBIO)

$51.37

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SBIO

AUM

$128425000

P/E ratio

17

Dividend yield

--

Expense ratio

0.5%

Beta

0.782394

Price on SBIO

Previous close

$50.57

Today's open

$51.05

Day's range

$51.05 - $51.96

52 week range

$22.33 - $52.90

Profile about SBIO

Headquarters

US

Exchange

NYSE Arca

Issue type

Exchange-Traded Fund

SBIO industries and sectors

Industries

Health

News on SBIO

Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?

Wall Street put up a modest show in the final quarter of 2025, with the S&P 500 advancing only 1.9%, the Dow Jones gaining 3.3% and the Nasdaq Composite adding about 2.1%. The small-cap index Russell 2000 added 1.6% during that period.

news source

Zacks Investment Research • Jan 6, 2026

news preview

ALPS ETFs in Biotech and Commodities Lead 2025 Gains

Biotech and natural resources funds led the ALPS ETFs lineup in 2025, with both strategies delivering returns above 45%, according to ETF Database. The ALPS Medical Breakthroughs ETF (SBIO) gained just over 57% through December 23, topping all ALPS products for the year, according to ETF Database.

news source

ETF Trends • Dec 26, 2025

news preview

Biotech ETF SBIO Hovers Near Peak on Rally

The ALPS Medical Breakthroughs ETF (SBIO) is trading close to its 52-week high of $51.87 after surging 10.51% in November, powered by a wave of positive clinical trial data and renewed merger activity in small- and midcap biotech companies, according to research from SS&C ALPS Advisors. The biotech ETF outpaced the Nasdaq Biotechnology Index's 8.

news source

ETF Trends • Dec 15, 2025

news preview

SBIO: A Shock Biotech Winner In 2025

The ALPS Medical Breakthroughs ETF has staged a remarkable comeback, outperforming despite a challenging macro backdrop and small-cap weakness. SBIO benefited from a rebound in FDA drug approvals, positive clinical news, and increased M&A activity as large pharma seeks pipeline replenishment. Risks remain high for SBIO, including sector volatility, unprofitability, sensitivity to interest rates, and potential regulatory or political headwinds.

news source

Seeking Alpha • Nov 28, 2025

news preview

Sabio Holdings Inc. (SBIO:CA) Q3 2025 Earnings Call Transcript

Sabio Holdings Inc. ( SBIO:CA ) Q3 2025 Earnings Call November 25, 2025 10:00 AM EST Company Participants Aziz Rahimtoola - Co-Founder, CEO & Chairman Sajid Premji - Chief Financial Officer Conference Call Participants Gabriel Leung - Beacon Securities Limited, Research Division Daniel Rosenberg - Paradigm Capital Inc., Research Division Nicholas Cortellucci - Atrium Research Corporation Presentation Operator Good morning, everyone, and welcome to Sabio Holdings Third Quarter 2025 Earnings Call. The financial statements and management discussion and analysis are available on SEDAR+.

news source

Seeking Alpha • Nov 25, 2025

news preview

Biotech Consolidation Could Perk Up, Lift This ETF

Regarding the healthcare sector again disappointing investors in 2025 — the largest ETF addressing the group is up just 11.39% — there are pockets of strength. Those include biotech stocks and the related ETFs.

news source

ETF Trends • Nov 19, 2025

news preview

Investing In Health Stocks - How Policy Clarity Is Opening Doors

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

news source

Seeking Alpha • Nov 11, 2025

news preview

3 Stocks Driving Biotech ETF SBIO's Appeal

In the shifting landscape of ETFs, many funds claim to offer exposure to innovation. Technology plays a key role as a growth industry and a driver for performance across the economy overall, as well.

news source

ETF Trends • Sep 11, 2025

news preview

This Underrated Tech ETF Is Spiking Amid Rate Cut Hype

Looking to add some diversification and upside to your equities allocation? While the broader tech space has largely relied on just a handful of names, smaller subcategories in innovative tech also have a role to play.

news source

ETF Trends • Aug 29, 2025

news preview

Is Biotech the Right Tech ETF Move Right Now? SBIO Argues Yes

The tech ETF space offers plenty of important questions for investors.

news source

ETF Trends • Aug 15, 2025

news preview

¹ Disclosures

Get started with M1

Invest in ALPS Medical Breakthroughs ETF

Open an M1 investment account to buy and sell ALPS Medical Breakthroughs ETF commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SBIO on M1